ReviewBiomarker research2026
ZDHHC5: a pivotal palmitoyltransferase orchestrating signaling networks - unraveling mechanisms and therapeutic horizons.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ZDHHC5, a key member of the DHHC family of palmitoyltransferases, catalyzes S-acylation-a reversible post-translational modification involving the covalent attachment of fatty acids, typically palmitate, to specific cysteine residues on target proteins. This lipid modification plays a critical regulatory role in protein trafficking, membrane association, stability, and the assembly of signaling complexes, thereby modulating diverse cellular processes such as cell proliferation, inflammatory signaling, and metabolic homeostasis. Accumulating evidence underscores the significant involvement of ZDHHC5 in various pathological states, particularly in oncogenesis and cancer progression. Nevertheless, the comprehensive landscape of ZDHHC5-regulated molecular networks across disease contexts remains incompletely understood. In this review, we summarize the structural architecture and catalytic mechanism of ZDHHC5, and elaborate on its biological functions with an emphasis on its role in major signaling pathways and disease pathogenesis. Furthermore, we assess the therapeutic potential of targeting ZDHHC5 through selective inhibitors, discuss current challenges and emerging opportunities in drug development, and highlight how artificial intelligence may accelerate the discovery of novel therapeutic strategies by enabling deeper mechanistic insights into ZDHHC5 function and regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.